Skip to main
RXST

RxSight (RXST) Stock Forecast & Price Target

RxSight (RXST) Analyst Ratings

Based on 9 analyst ratings
Hold
Strong Buy 11%
Buy 0%
Hold 67%
Sell 22%
Strong Sell 0%

Bulls say

RxSight Inc. is positioned for sustained double-digit growth, supported by an expanding light adjustable lens (LDD) installed base and increased utilization rates. The company's strategic initiatives to enhance LAL volumes, coupled with an increase in gross margin guidance for 2025—from 72-74% to 76-77%—indicate a strong focus on profitability and operational efficiency. In addition, RxSight's recent revenue performance surpassed consensus expectations, which, along with management's optimistic outlook on key financial metrics, underscores a robust potential for future growth.

Bears say

RxSight Inc. has experienced a significant decline in its financial performance, with revenue dropping 14% year-over-year to $30.3 million and a substantial decrease in light delivery device (LDD) placements, falling 68% year-over-year and 38% quarter-over-quarter. The company’s monthly utilization rates for its light adjustable lenses (LALs) have also declined, indicating a troubling trend in demand, as these metrics fell to 8.0 LALs per LDD in 3Q25, down from 8.7 in 2Q25 and 10.1 in 3Q24. Additionally, management has acknowledged several risks, including limited adoption of their technology, disappointing commercial execution, and increased competition in the intraocular lens market, all of which cast doubt on the company's future growth prospects.

RxSight (RXST) has been analyzed by 9 analysts, with a consensus rating of Hold. 11% of analysts recommend a Strong Buy, 0% recommend Buy, 67% suggest Holding, 22% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of RxSight and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About RxSight (RXST) Forecast

Analysts have given RxSight (RXST) a Hold based on their latest research and market trends.

According to 9 analysts, RxSight (RXST) has a Hold consensus rating as of Dec 30, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $9.44, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $9.44, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

RxSight (RXST)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.